Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
infectious disease
Biotech
YS Biopharma's rabies vaccine beats approved competitor in ph. 3
China’s YS Biopharma has a good feeling about a phase 3 trial of its investigational PIKA rabies vaccine based on an interim readout.
James Waldron
Apr 9, 2024 10:55am
Moderna touts 3 phase 1 data sets to bolster early vax work
Mar 27, 2024 3:21pm
J&J to close Bay Area R&D site less than 18 months after opening
Feb 25, 2024 6:43pm
Replicate's self-replicating RNA rabies vaccine clears phase 1
Feb 14, 2024 8:54am
Moderna joins 100 Days Mission to advance pandemic preparedness
Oct 30, 2023 9:21am
Vaccine-trial focused P95 buys South African CRO OnQ Research
Oct 17, 2023 10:30am